{"title": "PDF", "author": "PDF", "url": "https://sesmi.es/wp-content/uploads/2017/04/Programa.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": " \n \n \n          1 \n     Metabolic Correction Institute \u00a9 2016, 2017  \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n                      \n \n \n    \nTerapia Integrativa de Correci\u00f3n Metabolica:  \nCambiando el Paradigma  del C uidado de la \nSalud  \nIntegrative Metabolic Correction Therapy: Changing the  healthcare \nmanagement paradigm  \n \nC\u00e1ncer , Desordenes Endocrinos y N eurometab\u00f3licas  \nCancer, Endocrine Metabolic and Neurometabolic Dis orders  \n \nUniversity  Puerto Rico Certified  Program  Terapia Integrativa de Correcci\u00f3n  Metab\u00f3lica  \nIntegrative  Metabolic  Correction Therapy    \nMay 12 -13, 2017  \nValencia, Spain   \n \n \n          2 \n     Metabolic Correction Institute \u00a9 2016, 2017  \n SALUDOS             \n \nEstimados m\u00e9dicos, educadores e investigadores cl\u00ednicos:  \n \nLas gu\u00edas m\u00e9dicas dan al cl\u00ednico herramientas terap\u00e9uticas que han sido evidenciadas, \npero muchas veces los resultados obtenidos con estas estrategias est\u00e1n por debajo de \nlas expectativas deseadas. A veces, las gu\u00edas m\u00e9dicas alcanzan alivio sintom\u00e1tico o el \ncontrol de los factores de riesgo, pero no necesariamente la mejor\u00eda  significativa  o cura \ndel paciente. Sin embargo, un an\u00e1lisis exhaustivo puede revelar importantes factores \netiol\u00f3gicos en determinados individuos que al utilizarse adecuadamente puede corregir \nproblemas anteriormente no detectados y produciendo as\u00ed mejores resultados \nterap \u00e9uticos.  \n \nEl concepto de correcci\u00f3n metab\u00f3lica fue introducido como una manera de proponer un enfoque terap\u00e9utico \nseguro para llegar m\u00e1s all\u00e1 del remedio sintom\u00e1tico para reconocer y manejar las anomal\u00edas bioqu\u00edmicas \ncausantes de enfermedades  espec\u00edficas. Las reacciones bioqu\u00edmicas en nuestro cuerpo dependen usualmente \nde la disponibilidad de los precursores y enzimas metab\u00f3licas. Para alcanzar un estado fisiol\u00f3gico sano, el \norganismo requiere que las reacciones bioqu\u00edmicas se producen a una velocidad contr olada que produce el \nequilibrio saludable. Una compleja interacci\u00f3n de m\u00faltiples variables puede alterar este equilibrio. La Terapia \nde Correcci\u00f3n Metab\u00f3lica Integrada (TCMI) integra los principios de correcci\u00f3n metab\u00f3lica, con otros \nprincipios m\u00e9dicos bas ados en la ciencia que identifican y atienden las causas fundamentales del disturbio en \nla salud.  La TCMI atiende la interacci\u00f3n entre la composici\u00f3n gen\u00e9tica, los patrones alimentarios, \ntraumatismos, enfermedades, toxinas, medicamentos y factores de estr \u00e9s ambiental. Esta interacci\u00f3n produce \nlos cambios  tales como cambios en la microbiota, alteraciones en hormonas y neurotransmisores, inflamaci\u00f3n \nexcesiva, problemas autoinmunes, infecciones, acumulaci\u00f3n de t\u00f3xicos y demandas aumentadas de \nmicronutrientes.  TCMI incluye nutrici\u00f3n, suplementaci\u00f3n nutricional farmacol\u00f3gica, terapias oxidativas, terapias \ndetoxificadoras, infusiones ortomoleculares, terapia de reemplazos l\u00edpidos intravenosos y el uso apropiado de \nmedicamentos.  \n \nEn este curso se reunir\u00e1 el marco te\u00f3rico, el enfoque pr\u00e1ctico y la evidencia para hacer frente a varios aspectos \nimportantes en el paciente con c\u00e1ncer, trastornos metab\u00f3licos endocrinos y trastornos neurometab\u00f3licos \nselectos. Incluiremos una secci\u00f3n sobre desgaste de nutrientes y disfunci \u00f3n mitocondrial inducidos por \nmedicamentos.  \n \nComo parte del curso, adem\u00e1s de las pruebas cl\u00ednicas habituales, se discuten los contaminantes org\u00e1nicos \npersistentes, metales pesados, los desequilibrios nutricionales espec\u00edficos, desregulaciones inmunes, \nmarc adores de infecciones cr\u00f3nicas, las pruebas gen\u00f3micas y otros. Los resultados de estas pruebas permiten \nidentificar las causas fundamentales para desarrollar estrategias terap\u00e9uticas que mejoren los resultados \ncl\u00ednicos. Al repetir las pruebas se documenta la efectividad de la terapia. Los cl\u00ednicos que usen los protocolos \nde este curso pueden colaborar en investigaciones y publicaciones de MCI.  \n \n \nJorge R. Miranda -Massari,  Catedr\u00e1tico  \nDirector, Metabolic Correction Therapy Course  \n \nEl Instituto Correcci\u00f3n Met ab\u00f3lica (MCI) es una organizaci\u00f3n sin fines de lucro dirigida a desarrollar y llevar a cabo \ninvestigaci\u00f3n, educaci\u00f3n y servicios relacionados con las condiciones devastadoras, centr\u00e1ndose en sus causas \nsubyacentes. Esta iniciativa est\u00e1 dirigida al bienesta r humano mediante la maximizaci\u00f3n del uso de estrategias \neficaces y no t\u00f3xicas.  \n \n \n \n          3 \n     Metabolic Correction Institute \u00a9 2016, 2017  \n \nGREETINGS  \n \nDear Clinicians, Clinical Educators and Researchers:  \n \nStandard medical guidelines provide clinicians with therapeutic tools that have been \nwell studied; however, m any times the outcomes achieved with these strategies are \nbelow the desired expectations. Sometimes, medical guidelines achieve at most \nsymptomatic relief, or control, of risk factors. However, comprehensive examination can \nreveal important etiological fac tors in specific individuals that, when adequately treated \ncan correct previously undetected problems and therefore achieving better outcomes.  \n \nThe concept of metabolic correction was introduced as a way of proposing a safe therapeutic approach that \nwould go beyond symptomatic remedy to address the underlying biochemical abnormalities related to specific \nillnesses. Biochemical reactions in our body depend usually on the availability of precursors and metabolic \nenzymes. To achieve a healthy physiological sta te, the organism requires that biochemical reactions occur at a \nparticular controlled rate that produces a healthy equilibrium.  Complex interactions of variables can alter this \nequilibrium. The Integrated Metabolic Correction Therapy (IMCT) integrates the  principles of metabolic \ncorrection with other science based medical principles that focus on identifying and addressing the underlying \ncauses of the health problem. IMCT addresses the interaction between the individual genetics and the \nenvironmental stres sors. This interaction produces can produce significant changes that have impact in health \nsuch as alterations in the microbiota, hormones, neurotransmitters, excess inflammation, autoimmune diseases, \nchronic infections, toxin accumulation and increased mi cronutrient needs. An IMCT therapy includes nutrition, \npharmacologic nutritional supplementation, oxidative, detoxification therapies, orthomolecular infusions, \nintravenous lipid replacing therapy y optimal use of medications.  \n \nIn this course we bring toge ther the theoretical framework, the practical approach and research evidence to \ndeal with various important aspects in Cancer patients, metabolic endocrine disorders and selected \nneurometabolic disorders. We will also discuss about drug induced nutrient de pletion and mitochondrial \ndysfunction.  \n \nAs part of the course in addition to the usual laboratory clinical parameters includes, persistent organic \npollutants, heavy metals, specific nutrient imbalances, immune dysregulations, chronic infections, genomic \ntesting within others factors. The result of these laboratories allows identifying the underlying causes to \ndevelop therapeutic strategies that improve clinical outcomes. Repeating the tests document the effectiveness \nof therapy. The clinicians that use the protocols from this course cam collaborate in research and publications \nwith MCI.  \n \nSincerely,   \n \n \n \nProfessor , Jorge R. Miranda -Massari  \nDirector, Integrative Metabolic Correction Therapy Course  \n \nMetabolic Correction In stitute (MCI) is a 501(c)3 not -for-profit organization directed to develop and conduct \nresearch, education and services related to devastating conditions by focusing on its underlying causes. This \ninitiative is aimed to maximizing human wellbeing by the use of effective, non -toxic strategies.   \n \n \n \n          4 \n     Metabolic Correction Institute \u00a9 2016, 2017  \n  \n \n \n \nTerapia Integrativa de Correci\u00f3n Metabolica  \n \nC\u00e1ncer, Desordenes Endocrinos y Neurometab\u00f3licas  \n \nUniversity of Puerto Rico Certified Program  \nMay 12 -13, 2017  \n \nMeli\u00e1  Valencia Hotel  \nValencia, Spain  \n \n \n \nCOURSE DIRECTOR  \nProfessor, Jorge R. Miranda -Massar i, PharmD  \nUniversity of Puerto Rico  \n \nCOURSE FACULITY  \nAntonio Marco Chover, MD , Fernando Pinto, MD  \nKenneth Sotller, MD , Jesus  Caquias, MD  \n \n                                 \n  \n \nCOURSE FACULITY   \n \n \n          5 \n     Metabolic Correction Institute \u00a9 2016, 2017  \n \n \nCOURSE FACULITY   \n__________________________________ ______________________________________________________  \nJorge R. Miranda -Massari, PharmD  \nCatedr\u00e1tico en la Escuela de Farmacia, Universidad de Puerto Rico. Posdoctorado en \nFarmacocin\u00e9tica Cl\u00ednica de la Universidad de Carolina del Norte. Autor de sobre 100 \npublicaciones en revistas arbitradas por pares y dos libros. New  Insights on  Vitamin C and \nC\u00e1ncer de la Casa Publicadora  Springer  Publishing  (2014) y sobre el manejo Integrado de \nC\u00e1ncer por la casa Basic  Health  (2009). Es uno de los pioneros en el desarrol lo del concepto \nde la terapia de correcci\u00f3n metab\u00f3lica, Miembro electo a la Academia de las Artes y las \nCiencias de Puerto Rico y la Academia Ibero -Americana Cient\u00edfica y Cultural en 2014 y \nexaltado al Sal\u00f3n  de la Fama  Ortomolecular  en el 2016.  \n \nProfessor  at the University of Puerto Rico, School of Pharmacy  for over 25 years . Post-\ndoctorate in Clinical P harmacokinetics at University of North  Carolina. Dr. Miranda h as \nauthored over 100 scientific publications in peer -refereed  journals and two books; T he New \nInsights on Vitami n C and Cancer by Springer  Publishing in 2014 and Integrative Cancer \nManagement by Basic Health in 2009 . One of the pioneers of developing a concept of \nMetabolic Correction Therapy Approach. Inducted to the Academy of Arts and Sciences o f \nPuerto Rico in 2014 , the Ibero -American Scientific and Cultural Academy, and the Hall of \nFame from the International Orthomolecular Medicine in 2016.  The President of Metabolic \nCorrection Institute.  \n \n_____________________________________________________ _________________________________________________  \n \nKenneth Sotller, MD  \nEducado como pediatra en UCLA y miembro de la academia Americana de Pediatr\u00eda por \ndos d\u00e9cadas. Director m\u00e9dico  del grupo de Medicina Integrativa y Neurolog\u00eda de \nAzzolino en San Francis co, California. Director M\u00e9dico de Terapia de Oxigeno \nHiperb\u00e1rico de San Francisco. Miembro Vitalicio del Colegio Americano de Medicina \nHiperb\u00e1rica. Principal Oficial Medico de Veritas Medical  Diagnostics . \n \nDr. Stoller is an Assistant Professor at the AT  Still School of Medicine Arizona. He was \ntrained as a pediatrician at UCLA and was a fellow of the American Academy of \nPediatrics for two for two decades. Medical Director at the Azzolino Integrative Medicine \n& Neurology Group in San Francisco, CA. Medica l Director of Hyperbaric Oxygen \nTherapy of San Francisco. Dr. Stoller has been working with patients with brain injuries \nranging from traumatic brain injury, stroke, autism, cerebral palsy, MS, chemo -brain, and \nLyme brain since the late 1990s. Contributor of MCI Research Paper, Protocols  and \nTextbooks.                  __________ _________  \n \n \n FACULTAD   \n \n \n          6 \n     Metabolic Correction Institute \u00a9 2016, 2017  \n \n \n \nCOURSE FACULITY  \n________________________________________________________________________________________  \nAntonio Marco Chover , MD  \nGraduated medicine and surgery from  the University of Valencia. Diplomate in higher \nstudies in Sophrologic Medicine. Vicepresident of the ECPM (European Council of Doctors \nfor plurality in medicine). Professor at master program of natural medicine, acupuncture, \nhomeopathy and orthomolecular  medicine. Specialist in oxidation hemotherapy.  \n \nLicenciado en medicina y cirug\u00eda por la Universidad de Valencia. Diplomado en estudios \nsuperiores en Medicina sofrol\u00f3gica. Vicepresidente espa\u00f1ol del ECPM (European  Council of  \nDoctors for plurality  in medici ne).  Profesor de diversos masters sobre medicina naturista, \nacupuntura, homeopat\u00eda y  orthomolecular . Miembro de la Sociedad alemana HOT (terapia \npor oxidaci\u00f3n  hematogone ) \n \n___________________________________________________________________________________ _______________________________________________  \n \nJesus  Caquias, MD  \nMedicina General, Medicina Integrativa, ACAM, A4M, Certificado en Terapia de reemplazo de \nl\u00edpidos, Creador de protocolos de MCI y sobre 20,000 tratamientos intravenosos. (Comando \nfluido de  ingl\u00e9s y espa\u00f1ol)  \n \nGeneral Family Medicine, Integrative Medicine, ACAM, A4M,  Certified in  Lipid Replacement, \nChelation, Nutrients, V -C, and Oxidative Therapies. Dr. Jesus Caquias is a family medicine \ndoctor in Brownsville, Texas. He received his medical d egree from Meharry Medical College in \nNew York and has b een in practice for more than 25  years. Contributor  of MCI Protocols , \nResearch Paper, and Textbooks  with clinical experiences of over 20,00 Intravenous therapies . \nDr. Caquias is bilingual in English and Spanis h. \n_____________________________________________________________________________________________________________________________ _____  \n \n \n \n FACULTY  \n \n \n \n          7 \n     Metabolic Correction Institute \u00a9 2016, 2017  \n  \n \nDIA 1 (DAY 1)  Module I: Integrative Metabolic Correction Therapy in Cancer  \n 9:00 a.m.    Registration  \n 9:30 a.m. \u2013  9:45 a.m.  Welcome: Dr. A. Marco Chover and Professor, Jorge Miranda -Massari   \n    Pre-Exam  \n 9:45 a.m. \u2013 10:15  a.m. Epidemiology of Cancer  \n10:15 a.m. \u201311:30 a.m.  Metabolic Pathways in Cancer: The cell environment defines gene \nexpression and therefore differentiation. Some lifestyle factors are well \nknown to increase risk of cancer such as smoking and dietary nitrates. \nHowever, mitochondrial dysfunction is critical to cell energetics and \ndifferentiation. Will discuss the role of subacute chron ic infections, toxic \nmetals, organic toxins and medications in mitochondrial dysfunction in \ncarcinogenesis.  \n1. Mitochondria  \n2. Chronic infections and inflammatory processes as cancer risk factors:  \na. DNA/RNA Viruses  \nb. Fungal  \nc. Bacteria  \nd. NO \n3. Detoxification Pathways  \na. Xenob iotic Metabolism  \ni. Toxic Metals and Elements  \nii. Organic Toxins  \niii. Phase I and Phase II Drug Metabolism  \n4. Oxidative and Non -Oxidative Pathways  \n5. BCAA Metabolism  \n6. Signaling Pathways  \na. Insulin -like growth factor receptor signaling pathways  \nb. Ether Lipid Signaling Pathways  \n11:30 a.m. \u2013 11:45 a.m.  Q&A / Coffee Brake  \n11:45 a.m. \u2013 12:45 a.m.  Genetics and Epigenetics in Cancer  \n12:45 a.m. -  1:00 p.m.  Q&A  \n  1:00 p.m. -  1:45 p.m.  Integrative Cancer Assessment and Treatment Options I  \n7.  History and Physical Exam  \n8. Laboratory testing   \n9. Treatments  \na. Diet \nb. Supplements  \nc. Medications  \nd. Pain Management  SCHEDULE   \n \n \n          8 \n     Metabolic Correction Institute \u00a9 2016, 2017  \n 1:45 p.m. \u2013  2:00 p.m.  Lunch  \n  3:45 p.m. \u2013  5:00 p.m.  Integrative Cancer  Treatment Options II  \n10. Advanced Vitamin -C Therapies:  Antitumor agent, ascorbic acid acts \nthrough the inhibition of cell prog ression, increased levels of H2O2, \nantiproliferative effect of tumor cells, cytotoxicity and induction of \napoptosis. Dosing considerations and drug interactions must be \nconsidered for optimal response.  \n11. Detoxification Therapies : Reducing the toxic load of t oxic metals \nthat damage the mitochondria and the gene expression.  \ne. Chelation IV Therapies  \ni. DMPS  \nii. EDTA  \nf. GSH IV  \ng. Far Inferred Sauna Therapy  \n12. Lipid Replacement Therapies : Replacing damaged lipids in cellular \nmembranes and organelles.  This therapy has been shown t o reduce \nfatigue and restore mitochondrial function in cancer and non -cancer \npatients.  \n 5:00 p.m. \u2013 5:15 p.m.   Q&A / Coffee Brake  \n 5:15 p.m. \u2013 6:30 p.m.   Integrative Cancer  Treatment Options III  \n13. Oxidative Therapies:  Important in improving oxygenation and  \naerobic respiration and control of subacute -chronic infections.  \na. Ozone IV and IM  \nb. HBOT  \nc. Ultraviolet Blood I rradiation (UVBI)  \nd. H2O2 IV  \n14. Vitamins and Nutrients IVs  \ne. Mag IV/IM  \nf. MSM IV  \nLifestyle Recommendations in Cancer  \n15. Exercise, Home, Work and Spirituality  \n 6:30 p.m. \u2013 7:30 p.m.   4 Case Studies / Q&A / Discussions   \n    Post-Exam  \n \n  \n \n \n \n \n \n \n  \n \n \n          9 \n     Metabolic Correction Institute \u00a9 2016, 2017  \n DIA 2 (DAY 2)  Module II: Integrative Metabolic Correction Therapy in \nAutism Spectrum Disorder (ASD) /Neurometabolic and \nChronic Disease  \n 9:00 a.m.    Registrations  \n 9:30 a.m. \u2013 9:45 a.m .   Welcome: Dr. A. Marco Chover and Professor, Jorge Miranda -Massari  \n    Pre-Exam  \n 9:45 a.m. \u2013 10:00 a.m.  Background of Autism Spectrum Disorder (ASD)   \n16. Definition of ASD  \n17. Demography US and Spain  \n18. Mortality morbidity  \n19. QoL \n20. Costs  \n10:00  a.m. \u2013 11:30 a.m.  Genetic  Factors in ASD  \n21. Inborn Errors of Metabolism (IEM)  \nh. Metabolic Pathways in ASD  \ni. Neurotransmitters Pathway  \nii. Mitochondrial Pathway  \niii. Methylation Pathway  \niv. Urea Cycle E nzymopathies  \n22. Epigenetic factors  \ni. Environmental Toxics  \ni. Pesticides, Herbicides, Solvents, Polychlo rinated \nbiphenyl, Phthalates  \nj. Toxic Metals and Elements  \nk. Food intolerance  \ni. Gluten, Casein, others  \nl. Subcutaneous Infection  \nm. Drug Metabolism  \ni. Acetaminophen  \nn. Hormones  \n11:30 a.m. \u2013 11:45 a.m.  Q&A / Coffee Brake  \n11:45 a.m. \u2013 12:45 a.m.  Assessments and Treatments of ASD \n23. Medical  \no. History Form  \np. Physical Exam  \nq. Behavioral Assessment in Clinical Settings  \ni. ADOS  \n24. Problem Behaviors in ASD  \nr. Hyper Activities  \ns. Aggressive Behaviors  \nt. Sleep Disorder  \nu. Depression and others  \n25. Integrative Metabolic Correction Therapy:  Protocol for \nCustomized M anagement  \n26. Discussion of Case Studies  \n12:45 a.m. \u2013  1:00 p.m.  Q&A    \n \n \n          10 \n     Metabolic Correction Institute \u00a9 2016, 2017  \n   1:00 p.m. \u2013  1:45 p.m. Microbiome and Dysbiosis in Chronic Disease  \n27. Microbiot a \n28. Diet, Dysbiosis  \n29. Leaky Gut S yndrome  \n30. GALT and Immune system  \n 1:45 p.m. \u2013 3:45 p.m.  Lunch  \n 3:45 p.m. \u2013 5:00 p.m.  Metabolic and Mitochondrial Dysfunction in Chronic Disease  \n31. Drug induced nutrient depletion and Mitochondrial Dysfunction  \n32. Xenobiotics Metabolism and Specific pathways  \n 5:00 p.m. \u2013 5:15 p.m.   Q&A / Coffee Brake  \n 5:15 p.m. \u2013 6:45 p.m.  Integrative Metabolic Correction Therapy in Chronic Illness  \n33. Diabetes & Complications  \nv. Epidemiology and Pathophysiology   \n34. Chronic Fatigue and Adrenal F atigue  \n35. Multiple Sclerosis  \n36. Neuropathy  \n37. Micronutrients in DM  \n38. Integrative Metabolic Correction in Ophthalmology  \n39. Autoimmune Disease  \n 6:45 p.m. \u2013 7:30 p.m.   4 Case Studies and Discussions  \nPost-Exam  \n \n \n \n \n \n \n \n \n \nCancer Cell  \n \n \n \n  \n \n \n          11 \n     Metabolic Correction Institute \u00a9 2016, 2017  \n  \n \n \nDIA 1 (DAY 1)  \nCANCER  \n1. Identificando y Reduciendo Riesgos para el desarrollo  C\u00e1ncer \u25fe  Identifying  & Reducing  Cancer  Risks  \n1.1. Trasfondo (Definiendo c\u00e1ncer  y sus terapias ) \u25fe Background (Defining cancer and its treatments)  \n1.2. Epidemiolog\u00eda de las toxinas y c\u00e1ncer iatrog\u00e9nico \u25fe  Epidemiology  of toxins  and iatrogenic \ninduced cancer  \n1.3.  Disfunci\u00f3 n Mitocondrial  \u25fe Mitochondrial dysfunction  \n1.3.1.  Dieta \u2013 metabolismo, mitocondria y sistema inmunol\u00f3gico and  immune system  \u25fe Diet, \nMetabolism, mitocondria and  Immune system  \n1.3.1.1.  Perfil de macronutrientes \u25fe Macronutrients profile  \n1.3.1.2.  Perfil de micronutriente s \u25fe micronutri ents profile  \n1.3.1.3.  Sensibilidades  y alergias nutricionales  \u25fe Food allergies and sensitivities  \n1.3.2.  Infecci \u00f3n, inflamaci\u00f3n y mitocondria \u25fe  Infection , inflammation  and mitocondria  \n1.3.3.  Metales pesados y mitocondria \u25fe Heavy  metals  and mitocondria  \n1.3.4.  Contaminantes org\u00e1nicos  \u25fe Organic pollutants  \n1.4. Epigen\u00e9tica y v\u00edas Metab\u00f3licas  Secundarias en la Regulaci\u00f3n de D iferenciaci\u00f3n del C\u00e1ncer  \u25fe \nEpigenetics and Metabolic  Pathways  and Molecular  Regulation  in Cancer  \n1.5. Da\u00f1o y reparaci\u00f3n del DNA (DNA  damage  & repair ) Micronutrientes/contaminantes/i nfecciones  \u25fe \nMicronutrients /contaminants / infection ) Estilos de vida (Lifestyle ) \n1.5.1.  Dieta \u25fe Diet \n1.5.2.  Ejercicio \u25fe Exercise  \n1.5.3.  Descanso \u25fe Rest \n1.5.4.  Ambiente del hogar \u25fe Home  \nenvironment  \n1.5.5.  Ambiente  de trabajo  \u25feWork \nenvironment  \n1.5.6.  Espiritualidad \u25fe  Spirituality  \n1.5.7.  Otros factores  \u25fe Others Factors   \n2. Historial comprensivo y examen f\u00edsico completo \nPROGR AM   \n \n \n          12 \n     Metabolic Correction Institute \u00a9 2016, 2017  \n en el manejo de pacientes con c\u00e1ncer \u25fe Comprehensive  history  and complete  physical  exam  for \nmanagement  in cancer patients  \n3. Pruebas de laboratorio y aplicaciones cl\u00ednicas en el paciente con c\u00e1ncer  \u25fe Advanced  clinical \nlaboratory testing  and clinical applications for patients  with cancer  \n3.1.1.  Pruebas gen\u00f3micas  \u25fe Genomic testing  \n3.1.2.  Panel de micronutrients \u25fe Micronutrient panel  \n3.1.3.  Marcadores de c\u00e1ncer  \u25feCancer tumor  markers  \n3.1.4.  Marcadores  Metab\u00f3licos  \u25fe Metabolic Marke rs \n3.1.5.  Panel de hormonas \u25fe Hormone panel  \n3.1.6.  Panel de enfermedades infecciosas  \u25fe Infectious disease  panel  \n3.1.7.  Panel de metales pesados \u25fe Heavy  metals  panel  \n3.1.8.  Contaminantes org\u00e1nicos  \u25fe Organic contaminants  \n4. Manejo Avanzado de Vitamina C en C\u00e1ncer y otras terapias intraveno sas \u25fe Advanced Vitamin C and \nother IV treatments in Cancer  \n5. Manejo Metab\u00f3lico Comprensivo en el manejo del paciente con c\u00e1ncer \u25fe Comprehensive Metabolic \ntherapies in Cancer Management  \n5.1. Dieta  \u25fe Diet \n5.2. Oral Supplements \u25fe Suplementos Orales  \n5.3. Oral Medications \u25fe Medicamentos orales  \n6. Manejo  del dolor \u25fe Pain management  \n6.1. Consideraciones nutricionales  \u25fe Dietary considerations   \n6.2. Suplementos  \u25fe Supplements  \n6.3. Medicamentos  \u25fe Medications   \n7. IVC y enfermedades infecciosas  \u25fe IVC and  infectious diseases  \n7.1. Enfermedades virales (ej. herpes , varicela  zoster, EBV ) \u25fe Viral Infections  (i.e., herpes, varicela zoster, \nEBV) \n7.2. Infecciones Bacterianas  \u25fe Bacterial Infections ) (i.e.,  mycoplasma pneumonia , Lyme Borrelia \nBurgdorferi )  \n7.3. Infecc iones Fungales ( c\u00e1ndida ) \u25fe Fungal infections  (candida ) \n8. Terapia ox idativa para infecciones y reparaci\u00f3n tisular \u25fe  Oxidative  therapies  for infections  and tissue \nrepair  \n8.1. Ozono \u25fe Ozone  \n \n \n \n          13 \n     Metabolic Correction Institute \u00a9 2016, 2017  \n 8.1.1.  IV-Ozone, IM -Ozone  \n8.2. Oxigeno Hiperb\u00e1rico \u25fe  Hyperbaric Oxygen Therapy  in Cancer (HBOT)  \n8.3. Suplementaci\u00f3n de Oxigeno \u25fe Supplemented Oxygen  \n9. Terapia de reemplazo con l\u00edpidos \u25fe Lipid Replacement  Therapies   \n10. Referencias  \u25fe References  \n11. Cancer Research Collaboration with MCI  \n \nDIA 2 (DAY 2)  \nAUTISMO Y OTROS DESORDENES NEUROMETABOLICOS   \nAUTISM AND OTHER NEUROMETABOLIC DISORDERS  \n12. Terapia Integrada de C orrecci\u00f3n d e Metab\u00f3lica - Autismo \u25fe  Integrative Metabolic Correction Therapy \nin Neurometabolic Disorders \u2013 Autism  \n12.1. Trasfondo  \u25fe Background  \n12.2. Evaluaci \u00f3n \u2013Historial y  Examen \u25fe \nHistory Form , Exam , Assessments   \n12.3. Pruebas de laboratorio \u00fatiles \u25fe Useful \nLaboratory Testing   \n12.3.1.  Marc adores Gen\u00e9ticos  \u25fe Genetic \nMarkers  \n12.3.2.  Marcadores Biom\u00e9dicos  \u25fe Biomedical \nMarkers  \n12.4. Causas  M\u00e9dicas  Subyacentes  \u25fe \nUnderlying Medical Causes  \n12.4.1.  Errores Innatos del Metabolismo \u25fe  \nInborn  Error of Metabolism (IEM)  \n12.4.2.  Amino \u00c1cidos y \u00c1cidos Org\u00e1nicos \u25fe Amino  Acids  and Organ ic Acids  Metabolism   \n12.4.2.1.  Glycolytic Cycle Metabolites  \n12.4.2.2.  Oxalate Metabolites  \n12.4.2.3.  Krebs Cycle Metabolites  (Mitochondrial Markers)  \n12.4.2.4.  Amino Acids Metabolites (Mitochondrial and Detoxification Markers)  \n12.4.2.5.  Neurotransmitter Metabolites  \n \n \n \n          14 \n     Metabolic Correction Institute \u00a9 2016, 2017  \n 12.4.2.6.  Nutritional  \n12.4.2.7.  Pyrimidine Metabolites (Folate Metabolism ) \n12.4.2.8.  Fatty Acids Markers  \n12.4.3.  Disbiosis  Intestinal \u25fe Intestinal  Dysbiosis   \n12.4.3.1.  Conexi\u00f3n intestine -cerebro  \u25fe Gut-Brain \nConnection  \n12.4.4.  Toxins  \n12.4.4.1.  Quelaci\u00f3n  \u25fe Chelation  \n12.4.4.2.  Detoxificaci\u00f3n \u25fe Detoxification  \n12.4.4.3.  Estr\u00e9s oxidative \u25fe Oxidative Stress   \n12.4.5.  Intolerancia  a alimentos y Sistema immune \u25fe Food Intolerances  and Immun e System   \n12.4.6.  Infecciones \u25fe Infections  \n12.4.6.1.  DNA/RNA Viruses  \n12.4.6.2.  Fungal  \n12.4.6.3.  Bacteria  \n12.5. Aplicaciones Cl\u00ednicas  \u25fe Clinical Applications   \n12.5.1.  Intravenous therapy  (IV) \n12.5.2.  Rx \n12.5.3.  Suplementos \u25fe  Supplements  \n12.5.4.  Estilos de vida \u25fe  Lifestyle  \n12.5.5.  Hogar M\u00e9dico \u25fe  Medical Home   \n12.5.6.  Padres y hermanos \u25fe  Parents  and Siblings   \n13. Correcci\u00f3n Metab\u00f3lica de las neuropat\u00eda s y desordenes Neurometab\u00f3licos \u25fe  Integrative  Metabolic  \nCorrection Therapy  in Neurometabolic  Disorders  \n13.1. Neuropat\u00edas  \u25fe Neuropathies  \n13.2. Depresi \u00f3n \u25fe Depressions  \n13.3. Esclerosis  M\u00faltiple  \u25fe Multiple Sclerosis  (MS) \n13.4. Alzheimer\u2019s Disease  \n13.5. Esquizofrenia \u25fe Schizophrenia  \n14. Correcci\u00f3n Metab\u00f3lica  y Mitocondrial en Oftalmolog\u00eda \u25fe  \nMetabolic and Mitochondrial  Correction  in Ophthalmology   \n \n \n \n          15 \n     Metabolic Correction Institute \u00a9 2016, 2017  \n 14.1. Degeneraci\u00f3n  Macular \u25fe Macular D egeneration   \n14.2. Glaucoma \u25fe Glaucoma  \n14.3. Retinopat\u00eda  diabetic \u25fe Diabe tic Retinopathy  \n15. Autism Research Collaboration with MCI  \n \nENDOCRINE METABOLIC DISEASE  \n16. Endocrine  Metabolic  Disease   \n16.1. Diabetes \u25fe Diabetes  \n16.1.1.  Prevalencia \u25fe  Prevalence  \n16.1.2.  Fisiopatolog\u00ed a \u25fe Pathophysiology (glucose, excessive oxidation, toxic metabolites, \ninflammation, nitric oxide)  \n16.1.3.  Complicaciones  \u25fe Complications  \n16.1.4.  Correci\u00f3n  Metab\u00f3 lica en  Diabetes \u25fe Metabolic Correction in Diabetes (Diet and Key \nmicronutrients)  \n16.1.5.  Estudio de Caso  \u25fe Case  study  \n16.2. Enfermedad Tiroidea  \u25fe Thyroid disease   \n16.2.1.  Prevalencia  \u25fe Prevalence  \n16.2.2.  Fisiopatolog \u00eda \u25fe Pathophysiology  \n16.2.3.  Correci\u00f3n Metabolica  de Tiroides  \u25fe Metabolic Correction  Therapy  in Thyroid   \n16.2.4.  16.1.5.  Estudio de Caso \u25fe Case  Study \n16.3. Fatiga Cr\u00f3 nica y Adrenal \u25fe  Chronic  and Adrenal Fatigue s   \n16.4. Autoinmune \u25fe Autoimmune   \n16.5. Dolor  Cr\u00f3nico  \u25fe Chronic Pain   \n16.6. Hipertensi\u00f3n  \u25fe Hypertensions  \n16.7. Obesidad  \u25fe Obesity  \n16.8. Asma  \u25fe Asthma    \n17. Colaboraci \u00f3n en I nvestigaci\u00f3n en Diabetes \u25fe Diabetes  Research Collaboration  with MCI  \n \n \n \n  \n \n \n          16 \n     Metabolic Correction Institute \u00a9 2016, 2017  \n  \n1.1. Epidemiology of Toxins in \nChronic Disease and \nCancer  \n \nThe World Health \nOrganization has \ninformed that chronic, \nnon-infectious diseases \nare rapidly becoming \nepidemic worldwide. \nGrowing  rates of neurocognitive, metabolic, \nautoimmune, cardiovascular diseases and cancer \ncannot be attributed  only to genetics, lifestyle, and \nnutrition. It is now  increasingly recognized that early  \nlife and chronic exposures, of toxicants  may also \ncause chronic disease .1  \n \nThe President's Cancer Panel reported  in 2010  that \n\"the true burden of environmentally induced cancers \nhas been grossly underestimated\" and strongly urged \naction to reduce p eople's widespread exposure to \ncarcinogens . The panel advised  the President \"to use \nthe power of his office to remove the carcinogens and \nother toxins from our food, water, and air that \nincrease s health care costs, decreases our productivit y, \nand devastate  American lives. \" 2  \n \nUnderstanding about the role of toxic chemicals, nutritional imbalances, on the development of many \nchronic  is important to design more effective \ntreatments . Exposures to toxic or endocrine -\ndisrupting chemicals can influence metaboli sm, alter \nbrain growth   and play a substantial role in the \ndeveloping of respirator y diseases , neurobehavioral \ndisorders, mental disorde rs; obesity and type 2 \ndiabetes  and cancer.  3 \n \n1.2. Mitochondrial Dysfunction  \n \nCancer has been postulated as an energy \nproblem caused by a mitochondrial metabolic disease.  \nSeveral underlying mechanisms of deregulated \ncellular energetics are associated with mitochondrial \ndysfunction caused by mitochondrial DNA mutations, \nmitochondrial enzyme defects, or altered \noncogenes/tum or suppressors. Moreover, defects in \nmitochondrial enzymes are associated with both \nfamilial and sporadic forms of cancer.4 Dysfunctional \nmitochondria modulate cell cycle, gene expression, \nmetabolism, cell viability, and other established \naspects of cell g rowth and stress response .5 Metabolic \nenzymes of the Krebs cycle have been  newly  \nrecognised as oncosuppressors. Recent studies on \nindicate that modulation of mitochondrial respiration \nmay induce an arrest of cancer cell proliferation and \ndifferentiation and/or or death . This suggests  that \nmanipulation of some mitochondrial \nactivities may induce anticancer effects. 6 \n \n1.3. Epigenetics, \nMetabolic Pathways \nand Molecular \nRegulation in Cancer  \n \nEpigenetics is the study of changes \nin gene expression that does not involve \nchanges to the underlying DNA \nsequence but that  influences  how cells \n1. Identifying & Reducing Cancer Risks  \n \n \n \n          17 \n     Metabolic Correction Institute \u00a9 2016, 2017  \n read the genes. Epigenetic change can be influenced \nby factors such age, the environment , lifestyle, and \ndisease state.  \nThe m etabolic  alterations  produced by intake of \nsome nutri ents, drugs and chemicals  can occur by  \ndirectly  an impact  on epigenetic regulation.7  The \ngrowing u nderstanding how  metabolic pathways  are \naffected  by environmental and genetic factors  is \nexpected to  provide innovative  insights for the \ntreatment of  many  diseases. New technology will \nenable the analysis of large groups  of complex \nmolecular and clinical data for understanding how \ninflammation and mitochondria affect \nbioenergetics, epigenetics  and health. Energy \nutilization and disease are intimately connected by \nepigenetics . The improved interpretation of the \nmetabolo -epigenetic data of disease  will facilitate \ntherapeutic targeting linking nutritional toxicity and \nmetabolism.  \n \nMultiple molecular mechanisms  interact  to modulate  \ncentral  cellular metabolism and provide support for \nthe three basic needs of dividing cells: rapid ATP \ngeneration to maintain energy status; increased \nbiosynthesis of macromolecules; and reinforced \nmaintenance of appropriat e cellular redox status . 8 To \nmeet these necessities , cancer cell s acquire \nmodifications to the metabolism of all four major \nclasses of macromolecules: carbohydrates, proteins, \nlipids and nucleic acids. In the case of cancer cells, \nthese adaptations must be implemented in the \nstressful and dynamic microenvironment of th e solid \ntumor, where concentrations of crucial nutrients such \nas glucose, glutamine and oxygen are spatially and \ntemporally heterogeneous. 9 \n \nCancer development involves genetic and epigenetic \nalterations. Genetic marks are permanent, whereas \nepigenetic ma rks are dynamic, change with age, and \nare influenced by the external environment. Thus, \nepigenetics provides a link between the environment, \ndiet, and cancer development. Proper food selection \nis imperative for better health and to avoid cancer \nand other d iseases. Nutrients either contribute directly to cancer prevention or support the repair of \ngenomic and epigenomic damage caused by \nexposure to cancer -causing agents such as toxins, \nfree radicals, radiation, and infectious agents. \nNutritional epigenomics p rovides an opportunity for \ncancer prevention because selected nutrients have \nthe potential to reverse cancer -associated epigenetic \nmarks in different tumor types. A number of natural \nfoods and their bioactive components have been \nshown to have methylation -inhibitory and \ndeacetylation -inhibitory properties.  \n \nMitochondrial fu nction may contribute to cancer  \nthrough alterations in glucose metabolism, the \nproduction of reactive oxygen species (ROS) and \ncompromise of intrinsic apoptotic function. \nAlterations in c ancer glucose metabolism include the \nWarburg effect, leading to a shift in metabolism away \nfrom aerobic respiration toward glycolysis, even when \nsufficient oxygen is present to support respiration. \n10Such alterations in cellular metabolism may favor \ntumor c ell growth by increasing the availability of \nbiosynthetic intermediates needed for cellular growth \nand proliferation. Mutations in specific metabolic \nenzymes, have been linked to human cancer. \nMitochondrial ROS may contribute to cancer via DNA \ndamage and t he activation of aberrant signaling \npathways. ROS -dependent stabilization of the \ntranscription factor hypoxia -inducible factor (HIF) may \nbe a particularly important event for tumorigenesis. \n \n \n \n          18 \n     Metabolic Correction Institute \u00a9 2016, 2017  \n 11Compromised function of intrinsic apoptosis \nremoves an important cellular safeguard against \ncancer and has been implicated in tumorigenesis, \ntumor metastasis, and chemoresistance. Each of the \nmajor mitochondrial processes is linked.  Therefore, \nthe use on nutrients to improve or normalize the \nabnormal pathways that lead to carcinogenesis, cell \nproliferation and the restoration of apoptosis  can \nrepresent  potential  valuable therapeutic tools.   \n \n \n \n \n1.4. DNA Damage and Repair in \nCancer.  \n \nThe relevance of DNA damage and repair to \ncarcinogenesis became evident when it was \nrecognized that all agents that cause cancer \n(carcinogens) also cause a change in the DNA \nsequence and thus are mutagens.12  All the effects of \ncarcinogenic chemicals on tumor production can be \naccounted for by the DNA damage that they cause \nand by the errors i ntroduced into DNA during the \ncells\u2019 efforts to repair this damage. Likewise, \nultraviolet (UV) radiation and ionizing radiation can \nmodify DNA, and also cause cancer in animals and \ncan transform normal cells in culture into rapidly \nproliferating, cancer -type cells.  \n \n 1.5. Life Style  \n \nLifestyle factors (diet, body weight, physical \nactivity, and smoking) have been linked to a higher \nrisk of much medical comorbidity  (cardiovascular, \nmetabolic, etc.). There is increasing evidence linking \nthese factors to the ri sk of developing cancer and \nlikely cancer -related outcomes. 13 \n \nObesity  \n \nExcess body weight is a risk factor for multiple cancers. \nVarious molecular mechanisms have been put forth to \nexplain the association between body weight and \ncancer risk, including the  impact of low -grade chronic \ninflammation, elevated levels of leptin and \nadiponectin, altered levels of hormones and growth \nfactors (insulin, insulin -like growth factor -1, estrogens, \nand androgens), insulin resistance, and PI3K -AKT-\nmTOR signaling pathway a lterations.   \n \nDiet/Supplementation  \n \nDespite the demonstrated benefit of healthy eating \nhabits in cancer survivors, studies suggest that \napproximately 50% \u201370% of survivors do not meet the \ncurrent dietary guidelines. Glycemic load  has been \ndocumented to impa ct disease free and overall \nsurvival in stage III colon cancer patients, with higher \ndietary glycemic load significantly associated with \nworse disease -free survival among overweight or \nobese colon cancer survivors.14 The use of dietary \nsupplements in cancer has not been advocated in \nofficial guidelines, but there is a number of clinical \ntrials have demonstrated value in various aspects of \ncancer management such as, correcting nutrient \ninsufficiencies, decreasing adver se effects of \nchemotherapy, and improving quality of life.15 Dietary \nsupplements also can  be utilized to improve various \nmetabolic derangements  such as mitochondrial \ndysfunction , reduce toxicities , reduce  inflammation , \nimprove immune function, reduce oxidat ive stress all \nof which have potential benefits in various stages of  \n \n \n          19 \n     Metabolic Correction Institute \u00a9 2016, 2017  \n cancer rangin g from tumorigenesis to symptom \nimprovement.   \n \n \n \n1.6 Laboratory Testing  \n \nLaboratory tests in patients suspected to have cancer \nmay include blood or urine analysis and/or bi opsy of \na suspicious area, to assist  in the  arrival of the correct \ndiagnosis.  \nThe samples may show cancer cells, proteins or other \nsubstances made by the cancer  cells. Blood tests can \nalso reflect the functionality of certain organ systems \nand well as othe r variables that affect the process of \ncarcinogenesis, cell proliferation and metastasis.   \nOptimal clinical laboratory testing is a crucial tool for \nprevention, early detection and   monitoring of \nchronic conditions. In addition, optimal clinical lab testing should be used in an attempt to define the \nunderlying causes of the condition.  \nRisk factors for cancer include interactions of variables \nsuch as age, genetic background exposure to certain \nchemicals and specific physiologic processes such as \nChronic Inf lammation,  \nHormones, Immunosuppression , Infectious Agents, \nObesity and Radiation. Chemicals can include alcohol, \ntobacco, heavy metals, pesticides, organic \ncompounds and many others.16  \n \nHelpful Laboratory Testing for Cancer  \n\u25aa TK1 \n\u25aa Tumor  Markers  \n\u25aa Genomic Testing \n\u2713 IL-\u03b2, 1, 6, 17, 21 23, 27, etc.  \n\u2713 Others  \n\u25aa Inflammation  panel  \n\u25aa Environmental toxins  \n\u2713 Heavy metals  \n\u2713 Pesticides  \n\u25aa Infection panel  \n\u25aa Nutrient Panel  \n\u2713 Vitamins/Minerals  \n\u25aa Organic acid testing  \n\u2713 Mitochondrial function (OATS)  \n\u25aa Hormones  \n\u2713 Adrenal  \n\u2713 Thyroid  \n\u2713 Sex \n \n \n  \n \n \n          20 \n     Metabolic Correction Institute \u00a9 2016, 2017  \n  \n \n \nReferences:  \n \n                                                 \n1 Sears ME1, Genuis SJ. Environmental determinants of chronic disease and medical approaches: recognition, avoidance, \nsupportive therapy, and detoxification. Environm J Environ Public Health. 2012;2012:356798.  \n \n2 S.H. Reuben for the President's Cancer Panel, US Department of Health and Human Services, National Institutes of Health, \nNational Cancer Institute. Reducing Environmental Cancer Risk. What We Can Do Now, 2010, \nhttp://deainfo.nci.nih.gov/advisory/pcp/annualReports/pcp08 -09rpt/PCP_Report_08 -09_508.pdf . \n \n3 Sly PD, Carpenter DO, Van den Berg M, et al.Health Consequences of Environmental Exposures: Causal T hinking in Global \nEnvironmental Epidemiology. Ann Glob Health. 2016;82(1):3 -9. \n \n4 Hsu CC, Tseng LM, Lee HC. Role of mitochondrial dysfunction in cancer progression. Exp Biol Med. 2016;241(12):1281 -95. \n \n5 Boland ML, Chourasia AH, Macleod K. Mitochondrial dy sfunction in cancer. Front Oncol. 2013;3:292.  \n \n6 Scatena R. Mitochondria and cancer: a growing role in apoptosis, cancer cell metabolism and dedifferentiation. Adv Exp Med \nBiol. 2012;942:287 -308. \n \n7 Hern\u00e1ndez -Aguilera A1, Fern\u00e1ndez -Arroyo S, Cuy\u00e0s E, Lucia no-Mateo F, Cabre N, Camps J, Lopez -Miranda J, Menendez JA, \nJoven J. Epigenetics and nutrition -related epidemics of metabolic diseases: Current perspectives and challenges. Food Chem \nToxicol. 2016. pii: S0278 -6915(16)30272 -1. \n \n8 Harrelson JP, Lee MW. Expan ding the View of Breast Cancer Metabolism: Promising Molecular Targets and Therapeutic \nOpportunities. Pharmacol Ther. 2016. pii: S0163 -7258(16)30139 -5. \n \n9 Cairns RA, Harris IS & Mak TW. Regulation of cancer cell metabolism. Nature Reviews Cancer 2011;11:85 -95. \n \n10 Verma M. Cancer control and prevention: nutrition and epigenetics. Curr Opin Clin Nutr Metab Care. 2013;16(4):376 -84. \n Metabolic Correction Characteristics:  \n \n\u25aa Preventive  \n\u25aa Coordinated  \n\u25aa Evidence -based  \n\u25aa Optimizes physicians\u2019  treatment decisions making process  \n\u25aa Proactive and participatory, engaging patients in lifestyle choices  \n\u25aa Active health maintenance to compensate for genetic su sceptibilities  \nMetabolic correction therapy: Changing the healthcare management paradigm  \nDOI: 10.15761/IFNM.1000143  \n  \n \n \n          21 \n     Metabolic Correction Institute \u00a9 2016, 2017  \n                                                                                                                                                                             \n11 Fogg VC, Lanning NJ, Mackeigan JP. Mitochondria in cancer: at the crossroads of life and death. Chin J Cancer. 2011;30(8):526 -\n39. \n \n12 Lodish H, Berk A, Zipursky SL, et al. Molecular Cell Biology. 4th edition. New York: W. H. Freeman; 2000.  \n \n13 Vijayvergia N, Denlinger CS. Lifestyle Factors in Cancer Survivorship: Where We Are and Where We Are Headed. J Pers Med. \n2015;5(3):243 -63. \n \n14 Meyerhardt JA1, Sato K, Niedzwiecki D, Ye C, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Wigler DS, Venook \nA, Fuchs CS.Dietary glycemic load and cancer recurrence and survival in patients with stage III colon cancer: findings from C ALGB \n89803. J Natl Cancer Inst. 2012 Nov 21;104(22):1702 -11. \n \n15 Lis CG1, Cambron JA, Grutsch JF, Granick J, Gupta D. Self -reported quality of life in users and nonusers of dietary supplements \nin cancer. Support Care Cancer. 2006 Feb;14(2):193 -9. \n \n16 National Canc er Institute, NIH. Center causing substances  in the environment. http://www.cancer.gov/about -cancer/causes -\nprevention/risk/substances  \n ", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}